logo-loader
viewEdge Therapeutics

Shares in Edge Therapeutics rocket on results presentation news

Shares in the company jumped around 13.5% to US$7.72 on the news.

cancercell_56bb569d2f5d6.png
Edge uses microparticles to treat patients who have had a rare type of stroke

Shares in biotech firm Edge Therapeutics (NASDAQ:EDGE) rocketed as it announced the full set of results from its North American Phase I/II study of its EG-1962 treatment for NEWTON will be presented at the International Stroke Conference 2016.

The event will be held on February 17-19 at the Los Angeles Convention Center.

Shares in the company jumped around 13.5% to US$7.72 on the news.

The clinical-stage biotech firm is developing novel hospital-based therapies in the management of acute, life-threatening conditions.

Edge's lead product candidate, EG-1962, is in development to treat patients who have suffered a rare type of stroke known as aneurysmal subarachnoid haemorrhage, which can be the results of a ruptured brain aneurysm.

The data is from a Phase I/II trial, which, simply put was used to test whether microparticles can be used to treat patients who have suffered from the rare type of stroke

Quick facts: Edge Therapeutics

Price: - -

NASDAQ:EDGE
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Viva Gold kicking off PEA of Tonopah gold project in Nevada

Viva Gold Corp (CVE:VAU) (OTCBB: VAUCF) CEO James Hesketh tells Proactive the Nevada-based gold exploration and development company will begin its Preliminary Economic Assessment of its Tonopah gold project. Hesketh says that based on positive preliminary metallurgical results from its fall...

13 hours, 4 minutes ago

2 min read